DSM informs market of amended S-1 filing by Patheon N.V.

7/11/2016, 1:15 PM (Source: GlobeNewswire)

Royal DSM, a global science-based company active in health, nutrition and materials, informs its stakeholders that Patheon N.V., a company in which DSM holds approximately 53.5 million ordinary shares, has today commenced an Initial Public Offering.

As part of the Initial Public Offering, DSM is offering 4,878,049 of its ordinary shares in Patheon N.V. at an estimated price of between US$ 19.00 and US$ 22.00. Patheon N.V. will not receive any proceeds from the sale of ordinary shares by DSM.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the proposed offering may be obtained from:

 

J. P. Morgan Securities LLC
c/o Broadridge Financial Solutions
1155 Long Island Avenue
Edgewood, New York 11717
Attn: Prospectus Group 
Telephone: (866) 803-9204

Morgan Stanley & Co. LLC
180 Varick Street, Second Floor
New York, New York 10014
Attn: Prospectus Department

Jefferies LLC
520 Madison Avenue, 2nd Floor
New York, New York 10022
Attn: Equity Syndicate Prospectus Department 
Email:  Prospectus_Department@Jefferies.com
Telephone: (877) 547-6340

UBS Securities LLC 
1285 Avenue of the Americas 
New York, New York 10019 
Attn: Prospectus Department 
Telephone: (888) 827-7275

 

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission ("SEC") but has not yet become effective.  These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The statements in this press release that are not historical facts may be forward-looking statements. Such forward looking statements, based upon current beliefs and expectations, are subject to risks and uncertainties, which could cause actual results to differ from the forward looking statements. Accordingly, readers should not place undue reliance on forward-looking statements as a prediction of actual results. For more information concerning factors that could cause actual results to differ materially from those conveyed in the forward-looking statements, please refer to the "Risk Factors" section of the prospectus included in the registration statement, in the form last filed with the SEC. DSM does not assume any obligation to update the information contained in this press release.

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

 

DSM - Bright Science. Brighter Living.(TM)

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

 

For more information:

DSM Corporate Communications
Herman Betten
tel. +31 (0) 45 5782017           
e-mail media.contacts@dsm.com
DSM Investor Relations
Dave Huizing
tel. +31 (0) 45 5782864
e-mail investor.relations@dsm.com

 




This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DSM N.V. via Globenewswire

HUG#2027655
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.